deltatrials
Approved For Marketing EXPANDED_ACCESS NCT00438789

The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol (EMBRACE)

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Hemoglobinuria, Paroxysmal
Interventions eculizumab
Updated 10 times since 2017 Last updated: May 5, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Hemoglobinuria, Paroxysmal and is currently ongoing. Alexion Pharmaceuticals, Inc. leads this study, which shows 10 recorded versions since 2026 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotApproved For Marketing~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotApproved For Marketing~Jul 2017 – ~Apr 2018 · 9 months · monthly snapshotApproved For Marketing~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotApproved For Marketing~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotApproved For Marketing~Jan 2021 – ~Apr 2023 · 27 months · monthly snapshotApproved For Marketing~Apr 2023 – ~Dec 2023 · 8 months · monthly snapshotApproved For Marketing~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotApproved For Marketing~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotApproved For Marketing~Sep 2024 – present · 24 months · monthly snapshotApproved For Marketing

Change History

10 versions recorded

  1. Sep 2024 — Present [monthly]

    Approved For Marketing

  2. Jul 2024 — Sep 2024 [monthly]

    Approved For Marketing

  3. Dec 2023 — Jul 2024 [monthly]

    Approved For Marketing

  4. Apr 2023 — Dec 2023 [monthly]

    Approved For Marketing

  5. Jan 2021 — Apr 2023 [monthly]

    Approved For Marketing

▶ Show 5 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Approved For Marketing

  2. Apr 2018 — Jun 2018 [monthly]

    Approved For Marketing

    Phase: NA → None

  3. Jul 2017 — Apr 2018 [monthly]

    Approved For Marketing NA

    Phase: PHASE3 → NA

  4. Feb 2017 — Jul 2017 [monthly]

    Approved For Marketing PHASE3

  5. Jan 2017 — Feb 2017 [monthly]

    Approved For Marketing PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alexion Pharmaceuticals, Inc.
Data source: Alexion Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations